Replies to post #115550 on PharmaCyte Biotech Inc (PMCB)

[DragonBear]

Which btw, in case you haven’t heard, KW successfully pushed PharmaCyte through that development.

Here's nothing btw not heard much - there wasn't that much development to push through the last 8 yrs.

Prior post on the subject

What has Kenny and PMCB accomplished?

One regularly sees posts proclaiming Kenny, and PMCB have accomplished soooo much. Let's explore...

Creation of the cell line to produce the enzyme? Oops that was created back in the 1990s by AN.

Creation of the concept of encasing cells in a cellulose matrix? Oops, that was created back in the 1990s by AN.

Being able to successful encase cells in cellulose, and demonstrate their viability in an animal host? Oops that was performed back in the 1990s by AN.

Manufacture in a GMP? A win, but the manufacturing model was based on previous 1990s work trying to meet then EMA standards. No, complying with GMP-QC standards is not a great accomplishment.

Being able to demonstrate that when implanted in a pancreatic vein, they are unlikely to float off, and form a blood clot in the heart or have another side effect? Oops, Lohr ad hoc study 1999, with the cells he used half covered it. PMCB will still need to repeat the so called Lohr Phase 1, and that requires the mythical IND.

Those who wish to argue, the cells are improved, or the encasement has improved, congrads, yet two more reasons the FDA would reject a Phase 2b. The cells, and manufacturing must be consistent from one phase to the next in clinical testing.

The main accomplishment for Kenny, and PMCB is to revive a dead antiquated treatment concept by selling shares to retail. Whereas AN tried to fund through private equity, and went BK in 2003.

A startup biotech once out of the investigational stage, can sail through pre-clinical, through GMP, submit an IND, and be in clinical 1-1.5 yrs later. PMCB essentially started in a state 8 yrs ago when investigational work was already completed. It took 5 yrs just to get to pre-clinical. Then another 3 yrs to get to the stage where the mythical IND still hasn't gone in.

While this has been lumbering along going nowhere, a secondary accomplishment for Kenny is he has set himself up with a $1M/yr cash salary. Who cares about R&D funding. While also helping his CFO, along with Crabtree to have nice compensation. Various other BODs, consultants get smaller pieces of the pie. Let's not forget giving AN a pile of cash for a license off of a now expired patent.

Now Kenny has to figure out how to raise funds first for the salaries of the insiders, and then raise more for the FDA IND user fee. Unless he can get Homie's cousin to buy 5X more discounted private placement shares, it's going to be a long cold wait.